Eiger BioPharmaceuticals Inc. (EIGR) and Innoviva Inc. (NASDAQ:INVA) Contrasting side by side

Both Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) and Innoviva Inc. (NASDAQ:INVA) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eiger BioPharmaceuticals Inc. N/A 0.00 46.78M -3.98 0.00
Innoviva Inc. 261.00M 5.97 395.06M 1.65 10.69

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Eiger BioPharmaceuticals Inc. and Innoviva Inc.


Table 2 shows us the return on equity, return on assets and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Eiger BioPharmaceuticals Inc. 0.00% -155.6% -85.1%
Innoviva Inc. 151.36% -104.6% 60.2%

Risk and Volatility

Eiger BioPharmaceuticals Inc. has a beta of 1.43 and its 43.00% more volatile than Standard & Poor’s 500. Competitively, Innoviva Inc.’s 122.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.22 beta.


Eiger BioPharmaceuticals Inc.’s Current Ratio is 4.6 while its Quick Ratio is 4.6. On the competitive side is, Innoviva Inc. which has a 28.2 Current Ratio and a 28.2 Quick Ratio. Innoviva Inc. is better positioned to pay off short and long-term obligations compared to Eiger BioPharmaceuticals Inc.

Institutional & Insider Ownership

The shares of both Eiger BioPharmaceuticals Inc. and Innoviva Inc. are owned by institutional investors at 56.3% and 75.4% respectively. Insiders owned 7.3% of Eiger BioPharmaceuticals Inc. shares. On the other hand, insiders owned about 0.6% of Innoviva Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Eiger BioPharmaceuticals Inc. 5.75% -5.63% -11.3% -23.67% -11.65% -19.57%
Innoviva Inc. -3.5% 10.33% 21.27% 21.1% 36.8% 24.17%

For the past year Eiger BioPharmaceuticals Inc. had bearish trend while Innoviva Inc. had bullish trend.


On 10 of the 10 factors Innoviva Inc. beats Eiger BioPharmaceuticals Inc.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.

Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI). The company, under its the Long-Acting Beta2 Agonist (LABA) collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK), is entitled to receive royalties on the sales of RELVAR/BREO ELLIPTA; and a 15% of any future payments made by GSK under its agreements relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy and in combination with other therapeutically active components. It has LABA collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.